Patents by Inventor Anthony G. Doyle
Anthony G. Doyle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220185902Abstract: Recombinantly expressed variant antibodies that have enhanced affinity for TL1A and enhanced potency relative to the parent antibody from which they were derived are provided. The antibodies inhibit the interaction between TL1A and the death receptor 3 (DR3). The antibodies, or a composition thereof, may be used to treat one or more of asthma, COPD, pulmonary fibrosis, cystic fibrosis, inflammatory bowel disease, a gastrointestinal disease associated with cystic fibrosis, Crohn's disease, colitis, ulcerative colitis, irritable bowel syndrome, eosinophilic esophagitis, atopic dermatitis, eczema, scleroderma, arthritis, or rheumatoid arthritis.Type: ApplicationFiled: November 30, 2021Publication date: June 16, 2022Inventors: Lynn Dorothy POULTON, Matthew Pollard, Anthony G. Doyle, Bridget A. Cooksey, Vanya Pande, Adam W. Clarke
-
Patent number: 11220549Abstract: Recombinantly expressed variant antibodies that have enhanced affinity for TL1A and enhanced potency relative to the parent antibody from which they were derived are provided. The antibodies inhibit the interaction between TL1A and the death receptor 3 (DR3). The antibodies, or a composition thereof, may be used to treat one or more of asthma, COPD, pulmonary fibrosis, cystic fibrosis, inflammatory bowel disease, a gastrointestinal disease associated with cystic fibrosis, Crohn's disease, colitis, ulcerative colitis, irritable bowel syndrome, eosinophilic esophagitis, atopic dermatitis, eczema, scleroderma, arthritis, or rheumatoid arthritis.Type: GrantFiled: October 18, 2018Date of Patent: January 11, 2022Assignee: Cephalon, Inc.Inventors: Lynn Dorothy Poulton, Matthew Pollard, Anthony G. Doyle, Bridget A. Cooksey, Vanya Pande, Adam W. Clarke
-
Patent number: 10981986Abstract: The present invention provides a polypeptide construct comprising a peptide or polypeptide signaling ligand linked to an antibody or antigen binding portion thereof which binds to a cell surface-associated antigen, wherein the ligand comprises at least one amino acid substitution or deletion which reduces its potency on cells lacking expression of said antigen.Type: GrantFiled: March 2, 2017Date of Patent: April 20, 2021Assignee: Teva Pharmaceuticals Australia Pty LtdInventors: David S. Wilson, Jr., Sarah L. Pogue, Glen E. Mikesell, Tetsuya Taura, Wouter Korver, Anthony G. Doyle, Adam Clarke, Matthew Pollard, Stephen Tran, Jack Tzu Chiao Lin
-
Publication number: 20190106486Abstract: Recombinantly expressed variant antibodies that have enhanced affinity for TL1A and enhanced potency relative to the parent antibody from which they were derived are provided. The antibodies inhibit the interaction between TL1A and the death receptor 3 (DR3). The antibodies, or a composition thereof, may be used to treat one or more of asthma, COPD, pulmonary fibrosis, cystic fibrosis, inflammatory bowel disease, a gastrointestinal disease associated with cystic fibrosis, Crohn's disease, colitis, ulcerative colitis, irritable bowel syndrome, eosinophilic esophagitis, atopic dermatitis, eczema, scleroderma, arthritis, or rheumatoid arthritis.Type: ApplicationFiled: October 18, 2018Publication date: April 11, 2019Inventors: Lynn Dorothy Poulton, Matthew Pollard, Anthony G. Doyle, Bridget Ann Cooksey, Vanya Pande, Adam William Clarke
-
Patent number: 10138296Abstract: Recombinantly expressed variant antibodies that have enhanced affinity for TL1A and enhanced potency relative to the parent antibody from which they were derived are provided. The antibodies inhibit the interaction between TL1A and the death receptor 3 (DR3). The antibodies, or a composition thereof, may be used to treat one or more of asthma, COPD, pulmonary fibrosis, cystic fibrosis, inflammatory bowel disease, a gastrointestinal disease associated with cystic fibrosis, Crohn's disease, colitis, ulcerative colitis, irritable bowel syndrome, eosinophilic esophagitis, atopic dermatitis, eczema, scleroderma, arthritis, or rheumatoid arthritis.Type: GrantFiled: September 16, 2016Date of Patent: November 27, 2018Assignee: Cephalon, Inc.Inventors: Lynn Dorothy Poulton, Matthew Pollard, Anthony G. Doyle, Bridget Ann Cooksey, Vanya Pande, Adam William Clarke
-
Publication number: 20170233449Abstract: The present invention provides a polypeptide construct comprising a peptide or polypeptide signaling ligand linked to an antibody or antigen binding portion thereof which binds to a cell surface-associated antigen, wherein the ligand comprises at least one amino acid substitution or deletion which reduces its potency on cells lacking expression of said antigen.Type: ApplicationFiled: March 2, 2017Publication date: August 17, 2017Inventors: David S. Wilson, Jr., Sarah L. Pogue, Glen E. Mikesell, Tetsuya Taura, Wouter Korver, Anthony G. Doyle, Adam Clarke, Matthew Pollard, Stephen Tran, Jack Tzu Chiao Lin
-
Patent number: 9611322Abstract: The present invention provides a polypeptide construct comprising a peptide or polypeptide signaling ligand linked to an antibody or antigen binding portion thereof which binds to a cell surface-associated antigen, wherein the ligand comprises at least one amino acid substitution or deletion which reduces its potency on cells lacking expression of said antigen.Type: GrantFiled: April 28, 2014Date of Patent: April 4, 2017Assignee: Teva Pharmaceuticals Australia Pty LtdInventors: David S. Wilson, Jr., Sarah L. Pogue, Glen E. Mikesell, Tetsuya Taura, Wouter Korver, Anthony G. Doyle, Adam Clarke, Matthew Pollard, Stephen Tran, Jack Tzu Chiao Lin
-
Publication number: 20170081400Abstract: Recombinantly expressed variant antibodies that have enhanced affinity for TL1A and enhanced potency relative to the parent antibody from which they were derived are provided. The antibodies inhibit the interaction between TL1A and the death receptor 3 (DR3). The antibodies, or a composition thereof, may be used to treat one or more of asthma, COPD, pulmonary fibrosis, cystic fibrosis, inflammatory bowel disease, a gastrointestinal disease associated with cystic fibrosis, Crohn's disease, colitis, ulcerative colitis, irritable bowel syndrome, eosinophilic esophagitis, atopic dermatitis, eczema, scleroderma, arthritis, or rheumatoid arthritis.Type: ApplicationFiled: September 16, 2016Publication date: March 23, 2017Inventors: Lynn Dorothy Poulton, Matthew Pollard, Anthony G. Doyle, Bridget Ann Cooksey, Vanya Pande, Adam William Clarke
-
Publication number: 20160367695Abstract: The present invention provides a polypeptide construct comprising a peptide or polypeptide signaling ligand linked to an antibody or antigen binding portion thereof which binds to a cell surface-associated antigen, wherein the ligand comprises at least one amino acid substitution or deletion which reduces its potency on cells lacking expression of said antigen.Type: ApplicationFiled: June 28, 2016Publication date: December 22, 2016Inventors: David S. Wilson, Sarah L. Pogue, Glen E. Mikesell, Tetsuya Taura, Wouter Korver, Anthony G. Doyle, Adam Clarke, Matthew Pollard, Stephen Tran, Jack Tzu Chiao Lin
-
Patent number: 9127057Abstract: The present disclosure provides an isolated or recombinant IL-23-binding protein comprising an antigen binding domain of an antibody, wherein the antigen binding domain specifically binds to IL-23 but does not significantly bind to an IL-12p40 subunit and does not significantly bind to an IL-23p19 subunit when they are not components of IL-23. The present disclosure also provides uses of the IL-23-binding protein.Type: GrantFiled: July 20, 2011Date of Patent: September 8, 2015Assignee: Teva Pharmaceuticals Ausralia Pty LtdInventors: Adam William Clarke, Anthony G. Doyle, Matthew Pollard, Stephen Tran
-
Patent number: 8932588Abstract: The present invention provides a method of treating cancer in a subject wherein the cancer comprises mutated KRAS or BRAF genes. The method comprises administering to the subject an effective amount of an antibody or antigen binding fragment thereof wherein the antibody or antigen binding fragment thereof competes with SC104 for binding to the human colon cancer cell line Colo205.Type: GrantFiled: October 29, 2010Date of Patent: January 13, 2015Assignee: Teva Pharmaceuticals Australia Pty. Ltd.Inventors: Norbert A. Kienzle, Anthony G. Doyle, Tony Rowe
-
Patent number: 8901279Abstract: The present invention provides humanised antibodies and binding domains thereof with anti-tumor activity. In particular the humanised antibodies have specific binding to and direct killing of human colon tumor cells and display potent immune-mediated cytotoxic activity against human colon cancer cells in vitro using antibody-dependent cell-mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) assays and in vivo using mouse tumor models.Type: GrantFiled: May 21, 2013Date of Patent: December 2, 2014Assignee: Teva Pharmaceuticals Australia Pty LtdInventors: Adam W. Clarke, Anthony G. Doyle, Philip A. Jennings, Norbert Kienzle, Matthew Pollard
-
Publication number: 20140248238Abstract: The present invention provides a polypeptide construct comprising a peptide or polypeptide signaling ligand linked to an antibody or antigen binding portion thereof which binds to a cell surface-associated antigen, wherein the ligand comprises at least one amino acid substitution or deletion which reduces its potency on cells lacking expression of said antigen.Type: ApplicationFiled: April 28, 2014Publication date: September 4, 2014Applicant: Teva Pharmaceuticals Australia Pty LtdInventors: David S. Wilson, JR., Sarah L. Pogue, Glen E. Mikesell, Tetsuya Taura, Wouter Korver, Anthony G. Doyle, Adam Clarke, Matthew Pollard, Stephen Tran, Jack Tzu Chiao Lin
-
Publication number: 20130280246Abstract: The present invention provides humanised antibodies and binding domains thereof with anti-tumour activity. In particular the humanised antibodies have specific binding to and direct killing of human colon tumour cells and display potent immune-mediated cytotoxic activity against human colon cancer cells in vitro using antibody-dependent cell-mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) assays and in vivo using mouse tumour models.Type: ApplicationFiled: May 21, 2013Publication date: October 24, 2013Inventors: Adam W. Clarke, Anthony G. Doyle, Philip A. Jennings, Norbert Kienzle, Matthew Pollard
-
Patent number: 8470320Abstract: The present invention provides humanized antibodies and binding domains thereof with anti-tumor activity. In particular the humanized antibodies have specific binding to and direct killing of human colon tumor cells and display potent immune-mediated cytotoxic activity against human colon cancer cells in vitro using antibody-dependent cell-mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) assays and in vivo using mouse tumor models.Type: GrantFiled: March 16, 2010Date of Patent: June 25, 2013Assignee: Cephalon Australia Pty. Ltd.Inventors: Adam W. Clarke, Anthony G. Doyle, Philip A. Jennings, Norbert Kienzle, Matthew Pollard
-
Publication number: 20130115166Abstract: The present disclosure provides an isolated or recombinant IL-23-binding protein comprising an antigen binding domain of an antibody, wherein the antigen binding domain specifically binds to IL-23 but does not significantly bind to an IL-12p40 subunit and does not significantly bind to an IL-23p19 subunit when they are not components of IL-23. The present disclosure also provides uses of the IL-23-binding protein.Type: ApplicationFiled: July 20, 2011Publication date: May 9, 2013Applicant: CEPHALON AUSTRALIA PTY LTD.Inventors: Adam William Clarke, Anthony G. Doyle, Matthew Pollard, Stephen Tran
-
Publication number: 20130040383Abstract: The present invention provides a recombinant domain antibody (dAb) which binds to human TNF-?, the dAb comprising an immunoglobulin heavy or light chain variable domain, comprising at least one complementarity determining region (CDR) having a sequence derived from a New World primate.Type: ApplicationFiled: August 14, 2012Publication date: February 14, 2013Applicant: CEPHALON AUSTRALIA PTY LTD.Inventors: Benjamin P. Woolven, Ian M. Tomlinson, Jennifer A. Lee, Anthony G. Doyle, Philip A. Jennings
-
Publication number: 20120244151Abstract: The present invention provides a method of treating cancer in a subject wherein the cancer comprises mutated KRAS or BRAF genes. The method comprises administering to the subject an effective amount of an antibody or antigen binding fragment thereof wherein the antibody or antigen binding fragment thereof competes with SC104 for binding to the human colon cancer cell line Colo205.Type: ApplicationFiled: October 29, 2010Publication date: September 27, 2012Applicant: Cephalon Australia PTY LTDInventors: Norbert A. Kienzle, Anthony G. Doyle, Tony Rowe
-
Patent number: 8263076Abstract: The present invention provides a recombinant domain antibody (dAb) which binds to human TNF?, the dAb comprising an immunoglobulin heavy or light chain variable domain comprising at least one complementarity determining region (CDR) having a sequence derived from a New World primate.Type: GrantFiled: January 18, 2011Date of Patent: September 11, 2012Assignee: Cephalon Australia Pty Ltd.Inventors: Benjamin P. Woolven, Ian M. Tomlinson, Jennifer A. Lee, Anthony G. Doyle, Philip A. Jennings
-
Publication number: 20110237780Abstract: The present invention provides a recombinant domain antibody (dAb) which binds to human TNF-?, the dAb comprising an immunoglobulin heavy or light chain variable domain, wherein said variable domain comprises at least one complementarity determining region (CDR) having a sequence derived from a New World primate.Type: ApplicationFiled: January 18, 2011Publication date: September 29, 2011Applicant: Peptech LimitedInventors: Benjamin P. Woolven, Ian M. Tomlinson, Jennifer A. Lee, Anthony G. Doyle, Philip A. Jennings